Abstract

Objective: To compare estimates by bioimpedance spectroscopy analysis (BIS) of extracellular water (ECW), fat mass (FM), and fat-free mass (FFM) against standard techniques of bromide dilution and dual energy X-ray absorptiometry (DXA) during intervention that causes significant changes in water compartments and body composition.

Methods: Body composition analysis using BIS, bromide dilution, and DXA was performed in 71 healthy recreational athletes (43 men, 28 women; aged 18–40 years; BMI 24 ± 0.4 kg/m²) who participated in a double-blinded, randomized, placebo-controlled study of GH and testosterone treatment. The comparison of BIS with bromide dilution and DXA was analyzed using linear regression and the Bland–Altman method.

Results: At baseline, there was a significant correlation between BIS and bromide dilution-derived estimates for ECW, and DXA for FM and FFM (P < 0.001). ECW by BIS was 3.5 ± 8.1% lower compared with bromide dilution, while FM was 22.4 ± 26.8% lower and FFM 13.7 ± 7.5% higher compared with DXA (P < 0.01). During treatment, the change in ECW was similar between BIS and bromide dilution, whereas BIS gave a significantly greater reduction in FM (19.4 ± 44.8%) and a greater increase in FFM (5.6 ± 3.0%) compared with DXA (P < 0.01). Significant differences in body composition estimates between the BIS and DXA were observed only in men, particularly during the treatment that caused greatest change in water compartments and body composition.

Conclusion: In healthy adults, bioimpedance spectroscopy is an acceptable tool for measuring ECW; however, BIS overestimates FFM and substantially underestimates FM compared with DXA.
ECW measurements are of central importance in dissecting hormone effects on body composition, in particular on muscle mass, as approximate estimation of the functional compartment of muscle mass can be obtained by subtracting ECW from the FFM. Growth hormone (GH) and testosterone are known for their anabolic effects. However GH, particularly when combined with testosterone administration, results in fluid retention (13). Therefore, during these interventions, measuring FFM and FM against bromide dilution have been previously published (14).

## Methods

### Study design

We performed a double-blinded, randomized, placebo-controlled study of 96 healthy recreationally trained athletes, aged 18–40 years, who were in regular training (≥2 sessions per week) for the last 12 months. None of the women received any hormonal birth control medication. The data on body composition assessed by DXA and bromide dilution have been previously published (14). Women (n = 28) were randomized into two groups: i) GH (2 mg/day s.c.; n = 15) or ii) placebo (n = 13). Men (n = 43) were randomized into four treatment groups: i) GH (2 mg/day s.c.) plus testosterone (250 mg/week i.m.; n = 11); ii) GH plus placebo testosterone (n = 9); iii) testosterone plus placebo GH (n = 11); and iv) double placebo (n = 12). Body composition assessment with DXA, bromide dilution assay, and BIS were done at baseline (week 0), and during treatment (week 8), and these measurements were done on the same day. Due to equipment availability, BIS measurements were undertaken only on 53 subjects (female = 22, male = 31) at baseline and 71 subjects (female = 28, male = 43) during treatment. The St Vincent’s Hospital Human Research Ethics Committee approved the study and all subjects provided written informed consent before participation. The study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN012605000508673).

### Height and weight

Body weight was measured to the nearest 0.1 kg using an electronic scale (Tanita BWB-600) without shoes. Height was measured to the nearest 0.5 cm standing without shoes using a stadiometer (Holtain Ltd, Crymmych, Pembs, UK).

### Dual energy X-ray absorptiometry

FM and FFM were measured by DXA (Model DPX, software version 3.1, Lunar Radiation Corp., Madison, WI, USA). The coefficients of variation (CV) for FFM and FM are 1.4 and 2.9% respectively (15).

### Bromide dilution assay

Serum bromide was measured by HPLC. The serum samples were de-proteinated by centrifugation through a filtration unit with a cut-off size of 10 kDa (Amicon YM10, Millipore Corp., Bedford, MA, USA). The protein-free ultra-filtrate was...
passed through an anion exchange column (IC-Pak A, Waters Corp., Milford, MA, USA) at a flow rate of 0.35 ml/min and a detection wavelength of 195 nm. ECW was calculated from the change in the serum bromide concentration 140 min after injection of a known amount of bromide using the formula reported by Miller et al. (16): ECW (l) = 0.9 × 0.95 × Br dose (mmol)/Δ Br serum (mmol/l), where Δ Br serum is the change in serum bromide concentration, 0.9 is the correction factor for non-extra-cellular distribution of bromide, and 0.95 is the correction factor for Donnan equilibrium. For ECW inter-assay and intra-assay CV were 1.6 and 0.3% respectively (14).

Bioimpedance spectroscopy analysis

Body composition was assessed by BIS using the ImpediMed Ltd model SFB7 analyzer (ImpediMed Ltd, Brisbane, Queensland, Australia). SFB7 is a bioimpedance spectroscopy device that scans 256 frequencies from 4 to 1000 kHz. The measurement is based on an assumption that an electric current at low frequencies cannot permeate cells and travels through extra-cellular space only and is used to measure ECW. An electric current at high frequencies permeates cell membranes and is used to measure TBW. BIS estimates body composition using the mathematical model based on a Cole–Cole analysis (6). It uses the Hanai mixture theory, which models the body as a series of cylinders each having specific resistivity and gender-specific resistivity coefficients, which along with height and weight are used to calculate body fluid compartments (17). The following resistivity coefficients were used: pECW 310.0 and 316.2, and pICW 1018.0 and 1023.5 for males and females respectively. FFM is then derived by dividing TBW with the hydration constant 1023.5 for males and females respectively. FFM is then were used: pECW 310.0 and 316.2, and pICW 1018.0 and 1023.5 for males and females respectively.

Inter-assay and intra-assay CV for ECW were 2.2 and 0.2%, and for FM 4.3 and 1.2% respectively.

Statistical analyses

Regression analysis was used to determine the level of relative agreement between the different techniques. Bland–Altman analysis (19) with paired t-tests was used to determine the absolute limits of agreement between the body composition parameters assessed by DXA, bromide dilution, and BIS. Data are presented as means with s.d.s, unless otherwise stated. A P value of <0.05 was considered significant. Statistical analysis was performed using SPSS Statistics 20 (IBM Corp., Armonk, NY, USA).

Results

The baseline characteristics are summarized in Table 1.

Extracellular water

At baseline, there was a significant correlation between the bromide dilution assay and BIS for measuring ECW ($r^2 = 0.84; P < 0.001$). When compared with bromide dilution, ECW measured by BIS was significantly lower by $0.7 \pm 1.6$ l ($P < 0.01$; Fig. 1A).

During treatment, there was a significant correlation between the bromide dilution assay and BIS for assessing the amount of ECW ($r^2 = 0.84; P < 0.001$). ECW measured by BIS was significantly ($P < 0.05$) lower by 0.6 ± 2.0 l compared with ECW measured by bromide dilution.

BIS assessment of changes in ECW during treatment showed significant correlation with bromide dilution ($r^2 = 0.35; P < 0.001$). There was no significant difference in assessing changes in ECW between BIS and bromide dilution during treatment with GH, testosterone, or combined hormone administration (Figs 2A and 3A). There was no significant gender effect on changes in ECW content during hormone administration when comparing BIS with bromide dilution technique (Fig. 3A).

### Table 1 Baseline characteristics of subjects. Data are presented as means ± S.E.M.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Women ($n = 28$)</th>
<th>Men ($n = 43$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>29.4 ± 1.2</td>
<td>27.1 ± 0.8</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>167.4 ± 1.2</td>
<td>181.9 ± 1.0</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>64.0 ± 2.0</td>
<td>82.9 ± 2.5</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.8 ± 0.6</td>
<td>24.9 ± 0.6</td>
</tr>
<tr>
<td>IGF1 (µg/l)</td>
<td>124.8 ± 6.9</td>
<td>114.9 ± 6.4</td>
</tr>
<tr>
<td>Testosterone (nmol/l)</td>
<td>1.3 ± 0.1</td>
<td>23.4 ± 1.1</td>
</tr>
<tr>
<td>ECW (l) by bromide dilution</td>
<td>15.6 ± 0.3</td>
<td>21.8 ± 0.6</td>
</tr>
<tr>
<td>Fat-free mass (kg) by DXA</td>
<td>42.3 ± 0.9</td>
<td>64.0 ± 1.3</td>
</tr>
<tr>
<td>Fat mass (kg) by DXA</td>
<td>18.5 ± 1.3</td>
<td>15.1 ± 1.3</td>
</tr>
</tbody>
</table>
Thus, when compared with the reference method, BIS underestimated absolute levels of ECW by 3.5 ± 8.1% at baseline, whereas the change in ECW during treatment was similar when measured by either BIS or bromide dilution.

**Fat mass**

At baseline, there was a significant correlation between DXA and BIS for estimating FM ($r^2 = 0.79; P < 0.001$). When compared with DXA, FM measured by BIS was significantly lower by $3.9 \pm 3.7$ kg ($P < 0.001$; Fig. 1B).
Changes in BIS-derived FM during treatment significantly correlated with those derived by DXA ($r^2=0.24; P<0.001$). However, the change in BIS-derived FM was significantly lower by $1.2\pm 3.0$ kg ($P<0.01$; Fig. 2B). When the change in FM was analyzed separately for each of the treatment groups, the difference between the methods was confined to participants receiving GH, particularly when GH was combined with testosterone, which was highly significant ($P=0.001$; Fig. 3B). Moreover, this difference was noted in men but not in women (Fig. 3B).

Overall, when compared with DXA, BIS estimate of FM was consistently lower by $22.4\pm 26.8\%$ at baseline, and by $40.6\pm 47.9\%$ during treatment. Moreover, the measured reduction in FM during treatment was by $19.4\pm 44.8\%$ greater with BIS. In a subgroup of male participants receiving GH and testosterone-combined administration, the reduction in FM was $71.4\pm 46.1\%$ greater as estimated by BIS than by DXA.

### Fat-free mass

At baseline, there was a significant correlation between DXA and BIS for estimating FFM ($r^2=0.91; P<0.001$). However, BIS-derived FFM was by $7.2\pm 3.8$ kg higher than that measured with DXA ($P<0.001$; Fig. 1C).

During treatment, BIS also significantly correlated with DXA in assessing the amount of FFM ($r^2=0.91; P<0.001$). When compared with DXA, BIS-derived FFM was significantly higher by $7.9\pm 4.8$ kg ($P<0.001$).

Changes in BIS-derived FFM during the treatment showed significant correlation with those derived by DXA ($r^2=0.6; P<0.001$). When compared with DXA, there was a significantly greater increase by $1.0\pm 3.1$ kg in BIS-derived FFM ($P<0.05$; Fig. 2C). Assessing each treatment subgroup, the overestimation of changes in FFM were significant only in participants receiving combined GH and testosterone administration ($P<0.01$; Fig. 3C). As with FM, the difference between the methods in assessing FFM was noted only in men but not in women (Fig. 3C). The difference between the methods correlated significantly with the change in FFM during the treatment ($r^2=0.11; P=0.015$), reflecting greater overestimation of FFM by BIS in subjects with the highest increase in FFM.

We next calculated BCM, a functional cellular compartment within FFM, which is derived by subtracting ECW from the FFM. As with FFM, there was a significantly greater increase in BCM measured by BIS compared with the reference methods (Fig. 3D). The difference between the methods in assessing BCM was noted only in men, in
whom during combined GH and testosterone administration BIS overestimated change in BCM by 2.8 ± 1.2 kg (P < 0.001; Fig. 3D).

Overall, when compared with DXA, BIS estimate of FFM at baseline was 13.7 ± 7.5% higher and during the treatment was 13.8 ± 7.6% higher. The change in FFM was significantly different between the methods only in men, overestimating the change in FFM by 5.6 ± 3.0% and in BCM by 5.0 ± 2.6% during combined GH and testosterone administration.

Discussion
In this study of body composition, BIS-derived estimates of ECW, FM, and FFM correlated significantly with those obtained by bromide dilution and DXA in healthy young adults. However, BIS-derived measurements of ECW and FM were significantly lower and FFM significantly higher compared with the reference methods. Treatment with GH, testosterone, or both increased ECW and FFM and reduced FM. BIS-derived measurements of increase in ECW were similar to that estimated by bromide dilution. However, BIS recorded a significantly greater reduction in FM and a greater increase in FFM compared with DXA. These treatment differences in FM and FFM between methods were evident in men but not in women.

BIS utilizes a spectrum of frequencies between 4 and 1000 kHz, and employs Hanai mixture conductivity theory and the Cole–Cole model in the estimation of body fluid compartments, which is regarded more accurate than SFBIA or MFBIA (7, 20). The estimates are based on assumptions on body shape, tissue density, hydration, and are derived from resistivity coefficients that are gender specific (20). FFM is then estimated by the use of a hydration constant and with FM derived by subtracting FFM from the total body weight (6). Thus, the quantification of body composition by BIS depends on many factors and coefficients that can potentially result in measurement bias. A study in patients with GH deficiency reported that the bias can be diminished by applying unisex resistivity coefficients derived specifically from this patient population (21). As resistivity coefficients influence measurements by BIS, there is a need to develop coefficients derived from large populations, and incorporating factors, such as age, gender, hydration status, and BMI. Thus, the assumptions and coefficients inherent are likely factors that underlie errors in estimating fluid compartments and body composition by BIS.

This is the first placebo-controlled study comparing BIS with bromide dilution, a classical method for quantifying ECW, in a healthy population of lean men and women who received GH and/or testosterone administration. Our results show good agreement between the two methods. At baseline, there was only a 0.7 l difference in ECW, which represents a 3% lower estimate by BIS. Importantly, the change in ECW during 8 weeks of GH, testosterone and combined hormone administration showed no significant difference between the methods. Two previous studies evaluated acute shifts in ECW, one involving a hydration-/dehydration regimen in healthy men over 4 days and the other in men undergoing surgery. Both these studies reported good agreement between BIS and bromide dilution (22, 23). Thus, BIS is a reliable and accurate method for assessing changes in ECW.

In contrast to the good agreement between BIS and bromide dilution in measuring ECW, there was a marked disagreement in FM and FFM estimates between BIS and DXA. At baseline, BIS-derived estimate of FM was 22% lower and FFM 14% higher than those obtained by DXA in normal subjects. Previous studies comparing BIA and DXA have also reported similar bias (9, 10, 11, 12, 24). Importantly, our study observed that the reduction in FM and increase in FFM during GH and testosterone treatments quantified by BIS substantially differed from that of DXA. The largest discrepancy was for a change in FM, with the reduction in FM almost 20% greater than by DXA. Collectively, BIS significantly overestimates FFM and underestimates FM compared with DXA.

The observed difference between body composition estimates by BIS and DXA was particularly evident in men receiving GH alone or in combination with testosterone. These treatments resulted in the greatest increase in FFM, most of which is fluid retention (14). The impact of body composition change in determining BIS accuracy is supported by a weight loss study, which showed greater disagreement between BIS and the reference methods for TBW and ECW measures in patients with the greatest weight loss (25). As the amount of body water determines FFM and FM estimates by BIS, changes in tissue water may be associated with larger discrepancies between BIS and DXA-derived measures of body composition. Moreover, as TBW comprises ECW and ICW, the substantial difference in FFM and FM between the methods in the face of no significant discrepancy between BIS and bromide dilution in ECW estimate may reflect bias in ICW measurements by BIS. Thus, bias in water compartment assessment by BIS may be of the utmost importance in the determination of body composition measurements.

BIS estimates are based on the assumption that TBW comprises 73.2% of FFM and that this proportion does not...
change. There is a strong evidence that the hydration constant of FFM is not fixed and varies with many factors including the degree of adiposity. For muscle, a major component of the FFM, the average water content is 76% in normal-weight individuals but only 66% in obese subjects (26). Thus, the hydration of the FFM is influenced by the degree of adiposity. The increase in hydration derived from increase in TBW in our cohort was ~3% during GH or combined GH and testosterone administration in men. As BIS-derived FFM is estimated by dividing TBW by the hydration constant, an increase in hydration reduces the derived measure of FFM. Assuming that the average TBW in men is 45 l in our cohort, an increase in the hydration constant by 3% from 0.73 to 0.75 reduces FFM by 2.5 kg. Thus, the use of a fixed hydration coefficient introduces a systematic error that is likely to explain in part the overestimation of the FFM by BIS.

Our analysis uncovered interesting gender difference for change in soft tissue composition estimates. We speculate that the gender difference may be related with differences in gender-specific response to GH intervention, resulting in a smaller water retention in women compared with men. As hydration in women would have increased less than in men, it can be predicted that FFM shows better agreement with DXA in women than in men. Gender-related differences in responsiveness to GH may also introduce additional systematic bias. In our study, the absolute increase in DXA-derived FFM was lower in women than in men (2.7 vs 3.5 kg), in whom combined treatment with testosterone further increased FFM (6.4 kg). Thus, the increase in FFM was far greater in men than in women. As a component of the increase in FFM is ECW, the parallel increase in hydration will lead to a greater estimate of FFM by BIS, as was observed. More studies are required to develop hydration and gender-specific correction factors to improve the accuracy of estimating body composition by BIS in health and disease.

A reason for discrepancies between BIS and DXA may arise from assumptions used in DXA measurement of different tissue compartments. DXA estimates FFM on the basis of greater attenuation of X-rays going through lean tissue compared with fat tissue, not taking tissue water content into account. An increase in weight in parallel with an increase in FFM measured by DXA has been reported after normal saline infusion, reflecting errors in assessing FFM by DXA (27). Moreover, assessment of DXA compared with the four-compartment model has reported bias that varies according to the sex, size, fat amount, and disease state of the subjects, showing that DXA is unreliable for patients who undergo significant changes in body composition (28, 29). Thus, DXA is only assumed to be the reference standard method for measuring body composition. Measurement bias by DXA compared with the four-compartment model should be taken into account when comparing accuracy of other methods for body composition measurements, such as BIS, particularly when assessing significant changes in body composition.

In summary, BIS accurately estimates ECW, markedly underestimates FM, and overestimates FFM in healthy young adults. Importantly, when compared with DXA, the reduction in FM and increase in FFM during intervention was significantly greater by BIS. There was a gender difference for changes in FM and FFM, with the highest discrepancy between the methods in men who received combined GH and testosterone administration. This discrepancy may reflect the use of incorrect resistivity coefficients and/or hydration constant for deriving body composition estimates by BIS. The results reflect differences between BIS and the reference methods undertaken in healthy recreational athletes. The findings may be different in hypopituitary patients.

This is the first study systematically comparing BIS with bromide dilution and DXA in a healthy population of lean men and women undergoing intervention that results in significant changes in tissue water and body composition. We conclude that BIS is an accurate, time and cost-efficient method for estimating ECW; however, it overestimates FFM and substantially underestimates FM compared with DXA.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This study was supported by funding from The World Anti-Doping Agency and Australian Government Anti-Doping Research Program. The study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN012605000508673).

Acknowledgements
The authors thank Novo Nordisk for providing Somatropin and Organon for providing Sustanon.

References
1 Prior BM, Cureton KJ, Modlesky CM, Evans EM, Sloniger MA, Saunders M & Lewis RD. In vivo validation of whole body composition...


